This was more than just a survey—it was a collective step toward building a shared culture that reflects the diversity, strength, and vision of our entire organization. Your feedback will directly inform the actions we take as we continue our cultural transformation, shaping a workplace where every team member feels connected, valued, and inspired.

We’ll be sharing the key findings and outlining the next steps next month, and your feedback will directly inform the actions we take moving forward. This is a collective journey, and your participation is helping to build a culture that truly reflects who we are and what we strive to become.

Each of us brings something different to the table—unique perspectives, values, and approaches. That diversity is a powerful asset—and it calls us to be intentional in building a culture that unites us while honoring what makes each of us distinct.

Thank you again—for your engagement, your honesty, and your commitment to building a stronger, more unified Humaneva. Together, we are defining the values we live by, the behaviors we celebrate, and the workplace we’re proud to be part of.

Warm regards,

Tomek Dąbrowski, Chief Exec. Officer, Humaneva

🚀Our newest white paper, “𝗚𝗲𝗻𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆-𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗠𝗼𝗿𝘁𝗮𝗹𝗶𝘁𝘆: 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝘁𝗶𝗰 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗥𝗲𝗽𝗲𝗿𝗰𝘂𝘀𝘀𝗶𝗼𝗻𝘀, 𝗮𝗻𝗱 𝘁𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗟𝗲𝗻𝘁𝗶𝘃𝗶𝗿𝗮𝗹 𝗩𝗲𝗰𝘁𝗼𝗿𝘀 𝗶𝗻 𝗮 𝗛𝗲𝗶𝗴𝗵𝘁𝗲𝗻𝗲𝗱 𝗦𝗮𝗳𝗲𝘁𝘆 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲,” dives deep into the critical questions shaping the future of gene therapy.

A series of high-profile patient deaths in clinical trials—especially those involving adeno-associated virus (AAV) vectors—has triggered renewed regulatory scrutiny and sparked concern within the scientific community. In contrast, lentiviral vectors (LVVs), commonly used in ex vivo gene modification of hematopoietic stem cells, have continued to show a more favorable safety profile.

In this in-depth analysis, you’ll explore:

• The underlying mechanisms behind recent gene therapy-related mortalities

• How evolving regulatory frameworks are impacting the industry

• The unique safety profile and emerging role of lentiviral vectors in today’s landscape

Whether you’re a researcher, clinician, or biotech leader, this comprehensive analysis is essential reading for anyone navigating the challenges and opportunities in advanced therapies.

Read the full white paper and join the conversation

on how we can build a safer, more effective future

for gene therapy.

Oncoinformer (Onkoinformator) is Pratia’s free support service that helps oncology Patients and their families find and understand Clinical Trials in Poland. Our team guides them through available options—both at Pratia and beyond—and offers compassionate, expert support every step of the way.

Patients can reach us via a simple form at pratia.pl/onkoinformator or by calling our helpline (Mon–Fri, 8 AM–8 PM). We respond within 72 hours.

Why Oncoinformer?

Many Patients struggle to find relevant trials or understand complex medical information. Oncoinformer makes the process clearer, faster, and more human..

In the first quarter of 2025, our Polish Call Center handled 7,500 calls. 70% of them came from healthy volunteers interested in Phase I clinical trials. The remaining 30% were patients reaching out for specialist consultations or through the Onkoinformer.

But what these numbers don’t show is the human side. Behind all of this are just two people. Two voices who are the first contact point between our organization and the patient. They carry not only the practical responsibility, but the emotional and mental weight of every single call.

Being on the phone with patients day after day — many of them in difficult life situations — requires more than goodwill. It requires skill, emotional awareness, and psychological tools. That’s why we’re also proud to partner with the Lower Silesian Oncology Foundation to deliver communication training to our front-line specialists. Led by experienced psycho-oncologists, this program fills a critical gap in patient communication—equipping our team to offer empathy, attentiveness, and truly meaningful support.

Equally important was learning how to reset emotionally between calls, and how to stay grounded in self-compassion — reminding themselves: “You’re doing the best you can.”

Today, our Call Center team is not only better equipped — they’re more confident, more emotionally aware, and more prepared than ever to handle every call with professionalism, clarity, and human connection.

"I realized that if we want to care for patients in a meaningful way, we have to begin with the people who listen to them first. That’s why we focused on building not just their skills, but their emotional readiness — so they can offer patients both clarity and calm, even in the most difficult moments. Supporting patients often means working in the space between empathy and professionalism — being fully present, while also staying grounded and clear. For many people, the Onkoinformer is the first moment they feel genuinely heard. And that moment — that human connection — is where real support begins."

Breakthrough therapies, improved Patient care, and real progress in quality of life – that’s the impact we’re making together.

The international awareness campaign “Health has a future in clinical trials. Become the Patient of Tomorrow!” launched by Pratia in Poland in 2024 is expanding rapidly, and as of today, it has reached 8 countries across our global network. The campaign aims to raise public awareness about clinical trials, dispel myths, and highlight their true value—not only for individual patients but for the healthcare system as a whole.

Still, based on four blended survey reports “Opinions on Clinical Trials” conducted by Pratia in Poland, Bulgaria, Ukraine, and Czechia, over 40% of respondents admit they have little knowledge about them. This gap is a challenge—but also an opportunity. As professionals, we are in a unique position to close it with trusted information, empathy, and continued commitment.

Clinical research is more than procedures and protocols. It's about relationships, trust, and progress. As Pratia physicians emphasize, trials offer access to cutting-edge therapies not yet available in standard care, advanced diagnostics, and personalized support. Every participant has a story—often one of a chance for significant life improvement.

Thanks to efforts of investigators, study coordinators, recruitment teams, operations staff, lab specialists, QA professionals, CRAs, the Patients of Tomorrow are not just part of a campaign—they are living proof of how we’re changing medicine for the better.

Thank you to our Team for helping to drive this transformation forward. Together, we shape the future of medicine—starting today. Explore our Patients’ real stories and more below.

Each country-specific site offers locally tailored content in multiple languages. Topics range from “How Clinical Trials Work” and “Frequently Asked Questions” to interviews with healthcare professionals and up-to-date listings of open Clinical Trials.

It’s time to reflect on an inspiring gathering at the 11th edition of the “Clinical Trials Are for You” conference, organized to mark International Clinical Trials Day by INFARMA, POLCRO, and GCPpl. Pratia is proud to co-create this event as a member of the Organizing Committee.
This event was not only a valuable platform for discussions about the future of clinical trials in Poland and across Europe—it was also a great opportunity for the entire Pratia team to connect in person. Experts in Patient Engagement, Feasibility, Principal Investigators, Study Coordinators, and many more came together to share their insights and energy.
The conference reminded us how much we are united by a common purpose: to develop innovative approaches to clinical research. It also gave us the chance to strengthen relationships within our team—relationships that are essential to everything we do.
During the event, we explored key questions such as:
•How clinical trials can boost the resilience of healthcare systems and drive innovation,
•Whether Poland needs a national clinical trials strategy, and what it should include,
•The growing role of AI in transforming research,
•Opportunities offered by ATMP therapies,
•Quality management and the future of GCP standards,
•And what makes a truly attractive clinical trial site.
We are proud to have contributed to such important discussions—and even prouder to be part of a team shaping the future of medicine.

We are proud to announce that our abstract, titled “AI-driven integration of microbiome and exosome profiles for precision diagnostics and therapeutics in colorectal cancer,” has been accepted for presentation by both the American Society of Clinical Oncology (ASCO) and the American Society of Gene & Cell Therapy (ASGCT).

This dual recognition by two of the world’s leading scientific organizations reflects the groundbreaking nature of our work and the dedication of our entire team. Our research highlights the innovative application of artificial intelligence to integrate complex biological data, offering new pathways for precision diagnostics and personalized treatment in colorectal cancer.

Congratulations to Emile Youssef, Daniel Kowalski, Brandon Fletcher and Dannelle Palmer, who authored this paper, for this achievement! We look forward to sharing our findings with the global scientific community and continuing to push the boundaries of medical research together.

You can find the full abstract here:

Starting December 1st, the method of logging into NEUCAnet will change.

Below is the information about the planned changes:

Web address

The web address will remain the same: https://neucanet.neuca.pl

The login site

Below, you can find screenshots of the updated login page to guide you through the process:

Password

Password will not change. The password you are currently using will continue to work after December 1st.

Current login format: neuca/username (example: neuca/jdoe)

New login format (effective December 1st):

username@company.com

Examples:

jdoe@humaneva.com

jdoe@kapadi.com

jdoe@agaticlinical.com

jdoe@pratia.com

jdoe@hyggio.com

jdoe@neuca.com

For employees with a business email address:

After November 27th, you will receive an automatic email with information about your new login.

For employees without a business email address:

After November 27th, your manager will receive a list with your login details.

Need help?

If you encounter any difficulties logging in after December 1st, please reach out to your local HR representative or contact the IT Support / Service Desk.